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ABSTRACT
Cutaneous T-cell lymphomas (CTCL) are a
heterogeneous and relatively rare group of
non-Hodgkin lymphomas arising from
neoplastic skin-homing memory T cells. There
is no known cure for CTCL, and current
treatments focus on achieving and
maintaining remission, controlling symptoms,
limiting toxicities and maintaining or
improving quality of life. Patients with CTCL
often suffer from pruritus (itching), which can
be debilitating and can have a significant
impact on physical well-being and quality of
life. Although progress has been made towards
understanding the mechanisms of pruritus, the
pathophysiology of CTCL-related pruritus
remains unclear. Currently, there is neither a
step-wise treatment algorithm for CTCL nor a
standardized approach to treating pruritus in
patients with CTCL. Treatments which
specifically target pruritus have been reported
with varying effectiveness. However, systemic
treatments that target CTCL have the potential
to alleviate pruritus by treating the underlying
disease. Several systemic CTCL treatments have
reported anti-pruritic properties, some in both
objective responders and nonresponders, but
the lack of a standardized method to measure
and report pruritus makes it difficult to compare
the effectiveness of systemic treatments. In this
review, we provide an overview of approved and
investigational systemic CTCL treatments that
report anti-pruritic properties. For each study,
the methods used to measure and report
pruritus, as well as the study design are
examined so that the clinical benefits of each
systemic treatment can be more readily
evaluated.
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OVERVIEW OF CUTANEOUS T-CELL
LYMPHOMA AND THE BURDEN
OF PRURITUS
Cutaneous T-cell lymphomas (CTCL) are a
heterogeneous group of relatively rare
lymphomas that comprise &4% of
non-Hodgkin lymphoma cases diagnosed in
the United States [1, 2]. CTCLs are caused by
malignant helper T-cells that express a memory
phenotype and localize to the skin [3, 4].
Mycosis fungoides (MF) and its leukemic
variant Se´zary syndrome (SS) are the most
common forms of CTCL [2, 5]. Patients with
CTCL typically present with erythematous
patches in sun-protected areas, although
visible changes to the skin can include any
combination of patches, plaques, papules,
tumours, and/or erythroderma [6, 7]. Correct,
timely diagnosis of CTCL can be difficult
because the clinical presentation and histology
can resemble more benign conditions (e.g.,
eczema, psoriasis, other inflammatory
dermatoses) and patients may initially have
skin improvement with treatments for these
conditions [8–10].
Although CTCL arises in the skin, advanced
stages are associated with systemic involvement
(lymph nodes, blood, visceral organs), with
markedly reduced survival in advanced disease
[7, 11]. In addition to physical burdens of
disease, CTCL can also have a significant
impact on patient emotional, functional, and
psychological well-being and negatively impact
quality of life (QOL) [12]; QOL worsens with
disease progression [13]. The majority of
patients with CTCL experience pruritus
(itching), [12–15] often as the first symptom of
disease [6]. Pruritus has been demonstrated to
negatively impact patient QOL [12, 13]. For
example, pruritus can interfere with sleeping
patterns and impede daily activities, and
patients with prolonged symptoms may
require treatment for depression and insomnia
[16]. Patients can experience severe pruritus
regardless of disease stage, [13] although the
incidence and severity of pruritus often worsens
as the disease progresses [14]. In advanced
CTCL, patients also commonly experience
‘‘burning pain’’ and sharp ‘‘pins and needles’’
[17]. The incidence and severity of pruritus are
more pronounced with certain subsets of CTCL.
Se´zary syndrome is typically associated with
severe pruritus, as well as generalized
erythroderma and blood involvement with or
without lymphadenopathy [10]. In a
retrospective analysis of patients with CTCL
(N = 551), 94% of patients with SS experienced
pruritus compared with 61% with MF [14] and
the mean pruritus score on a 10-point scale was
7.7 vs 3.6 for patients with SS and MF,
respectively (P\0.001). Folliculotropic MF is
an aggressive variant of MF also associated with
significant pruritus [10, 15, 18].
Currently, pruritus intensity is most often
measured via a patient-reported visual analog
scale (VAS) [19]. The VAS was first developed as
a system to rate employees and has been
subsequently adapted to measure pain,
feelings, and other subjective criteria that
cannot be directly measured or assessed by an
external evaluator [13, 20–24]. For the VAS, the
patient is given a line of fixed length where the
end points are labelled and described (e.g., ‘‘no
itching’’ to ‘‘unbearable itching’’) [22, 25].
Patients are instructed to mark on the line
corresponding to their perceived state of
itching.
Current CTCL treatments are focused on
inducing and maintaining remission,
controlling symptoms, limiting toxicities, and
maintaining patient QOL [26, 27]. Given the
impact of pruritus on patient QOL and the
potential link to reduction in disease,
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treatments that alleviate pruritus can provide a
significant clinical benefit for patients with
CTCL.
MECHANISMS OF PRURITUS
IN PATIENTS WITH CTCL
Considerable advances towards understanding
the mechanisms of pruritus have been described
[28, 29]. However, the pathophysiology of
CTCL-related pruritus remains unclear.
Patients with CTCL may experience pruritus
on skin lesions or uninvolved skin, even before
other skin-related symptoms manifest
[6, 16, 30]. These observations suggest that a
soluble pruritic factor could be generated locally
at the diseased skin or elsewhere in the body
[16]. CTCL-related pruritus does not typically
respond well to anti-histamine treatments,
suggesting that mediators other than
histamine may be involved [30, 31].
The cytokine expression profile of malignant
T cells in CTCL is complex. A Th1-like profile
has been observed in early-stage MF, while a
Th2-like profile has been observed in later-stage
MF and SS [32–34]. Recently, significantly
higher levels of interleukin (IL)-31 have been
found in patients with pruritic skin diseases
compared to those without [35]. Reports have
shown that patients with CTCL-related pruritus
also had higher levels of IL-31 than those
without and resolution of pruritus correlated
with a decrease in IL-31 [36]. In another study,
levels of IL-31 and severity of pruritus were
correlated for patients with stage IB CTCL [30].
Interestingly, in vitro treatment of peripheral
mononuclear blood cells (PBMCs) from patients
with stage III-IV CTCL with vorinostat or
dexamethasone suppressed production of
IL-31. Treatment of patients (n = 2) with stage
IV CTCL with a single dose of intravenous (IV)
romidepsin resulted in suppressed production
of IL-31 in PBMCs and a reduction in pruritus
[37]. The majority of IL-31–producing T cells
also express the skin-localizing receptor CC
chemokine receptor 4 (CCR4), [37] and
treatment of a patient with stage IV CTCL
with the anti-CCR4 antibody mogamulizumab
reduced pruritus and suppressed production of
IL-31 in PBMCs [37].
The neuropeptide substance P, which is
released from the ends of cutaneous sensory
nerves, is an agonist of the neurokinin-1
receptor and has been implicated in itch
[31, 38]. Use of aprepitant, which blocks the
neurokinin-1 receptor, has been shown to
relieve CTCL-related pruritus [39, 40]. Opioid
receptors have also been implicated in pruritus
[41]. Naloxone, an opioid receptor antagonist,
has been found to reduce pruritus in patients
with MF [42]; naltrexone, which also
antagonizes opioid receptors, has been used
with mixed results in patients with MF [6, 42].
Also, the proteinase-activated receptor 2 is
located on cutaneous sensory neurons and has
been found to mediate pruritus in atopic
dermatitis, [43] which favours a Th2 cytokine
profile similar to that of late-stage MF/SS [44].
Although central and peripheral-acting
mediators have been proposed, the exact
mechanisms of CTCL-related pruritus remain
unclear, and further understanding of the
pathophysiology of CTCL-related pruritus may
provide new avenues for treatment.




National comprehensive cancer network
(NCCN) guidelines recommend several topical
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and systemic anti-pruritic treatments for
CTCL-related pruritus [45]. However, as
CTCL-related pruritus is ultimately a result of
the lymphoma, controlling the disease may be
an effective way to manage itch. Skin-directed
phototherapies [psoralen and ultraviolet A
(PUVA) and ultraviolet B (UVB)] have
demonstrated the ability to induce remissions
in early-stage disease, but few data are available
regarding reduction of CTCL-related pruritus
[45, 46]. In several case studies, treatment with
PUVA resulted in improvement of pruritus in
patients with Se´zary syndrome [47, 48]. The
effect of narrowband UVB on reduction of
pruritus has been reported, but limited data
are available in the context of CTCL [49, 50].
Other topical anti-lymphoma treatments such
as carmustine, retinoids, and mechlorethamine
(nitrogen mustard) have demonstrated
effectiveness in inducing objective responses
in early-stage MF, but may induce skin-directed
adverse events that exacerbate pruritus rather
than relieve it [5, 31, 51, 52]. Interestingly, a
case series of 11 patients with CTCL treated with
topical mechlorethamine resulted in the
disappearance of pruritus [53]. A number of
systemic anti-CTCL agents have documented
anti-pruritic effects, but methods of pruritus
assessment and data reporting vary across
studies. In the following sections, we present
studies of systemic anti-lymphoma agents, the
method of pruritus assessment (if included),
and the effects of each treatment on pruritus
(Table 1). Inclusion of systemic anti-lymphoma
agents in this narrative review was initially
based on NCCN recommended agents. PubMed
was searched for literature describing these
recommended treatments with a focus on
clinical trials which included assessments of
pruritus. Additional papers were added to this
initial literature through supplementary ad hoc
searches.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Romidepsin
Class I selective histone deacetylase (HDAC)
inhibitor [54] romidepsin (IV) is approved for
patients with CTCL who have received C1 prior
systemic therapy, [55] primarily based on results
from a pivotal phase II study in patients
(N = 96) with stage IB–IVA CTCL and C1
previous systemic treatment (a National
Cancer Institute trial that supported the
approval did not incorporate an assessment of
pruritus) [22, 56, 57]. In the pivotal study, the
majority of patients (60/65, 92%) with
moderate to severe pruritus at baseline
reported a reduction in their VAS score (mean
change of -38 mm). Clinically meaningful
reduction in pruritus (CMRP) was observed in
28/65 patients (43%) with moderate to severe
pruritus at baseline—including 19/36 patients
(53%) with severe pruritus at baseline. Seven
patients with severe pruritus at baseline
achieved complete resolution of pruritus for
2–8 months. Overall, the median time to CMRP
was 1.8 months and the median duration of
CMRP was 5.6 months. For patients with
objective disease responses, 17/26 (65%)
achieved CMRP, including 5/5 patients with
complete response. However, CMRP also
occurred in nonresponders (11/39, 28%)—all
with best response of stable disease (SD).
Patients were also able to achieve CMRP
irrespective of disease compartment
involvement; although lymphadenopathy
significantly lowered rates of CMRP,
erythroderma, blood involvement, and higher
blood tumour burden (surrogate for SS) did not
[58].
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In evaluable patients with folliculotropic
disease involvement (n = 9), patients with
moderate to severe pruritus at baseline had a
mean reduction in VAS of -53 mm (-60 mm
for those with severe pruritus) and 1 patient had
complete resolution of pruritus [59]. In
evaluable patients with cutaneous tumours
(n = 19), patients with moderate to severe
pruritus had a mean reduction in VAS of
-43 mm (-45 mm for those with severe
pruritus) and two patients had complete
resolution of pruritus [59]. In evaluable
patients who received prior systemic
chemotherapy (n = 50), 24 (48%) experienced
CMRP [60].
Bexarotene
Retinoid bexarotene (oral) is approved for the
treatment of cutaneous manifestations in
patients with CTCL refractory to C1 prior
systemic therapy [61]. In a phase II/III study
in patients (N = 94) with stage IIB-IVB CTCL
refractory to C1 systemic anti-cancer therapy,
the mean pruritus score at baseline was
reduced at week 48 regardless of concomitant
antihistamine/antipruritic treatment [62]. In a
phase II/III study of patients (N = 58) with
stage IA-IIA refractory CTCL (or who were
intolerant to or reaching a 6-month plateau
to prior treatment), pruritus for representative
index lesions decreased from mild-moderate at
baseline to mild-absent by week 16 [63].
Pruritus continued to improve independent of
additional anti-histamine and/or anti-pruritic
use. Additionally, a phase II trial was
conducted to examine doxorubicin
hydrochloride (HCl) followed by bexarotene
in patients (N = 37) with stage IB-IV CTCL (or
stage IB-IIA disease poorly responsive to
skin-directed therapies) [64]. Following
treatment with doxorubicin HCl, 53% of
patients had pruritus relief (5/9 responders;
3/6 patients with SD), and following
subsequent bexarotene treatment, 71% of
patients had pruritus relief (3/5 responders;
2/2 patients with SD). In a pilot study of
bexarotene in combination with rosiglitazone
in patients (N = 4) with stages IA-IVA CTCL
with SD or partial response to single-agent
bexarotene, pruritus was alleviated in 3
patients (75%) [65].
Denileukin Diftitox
Diphtheria toxin/IL-2 fusion protein denileukin
diftitox (DD; IV) is approved for persistent or
recurrent disease that expresses CD25 [66];
however, it is undergoing reformulation and
has been withdrawn from the market [45]. In a
phase III study of patients (N = 144) with
CD25? stage IA–III CTCL who had received
B3 prior therapies, clinically significant
improvement in pruritus was reported in 9.1%
of patients with placebo vs 13.3% with DD 9 lg/
kg/days (P = 0.7681) and 34.5% with DD 18 lg/
kg/days (P = 0.0048) [67]. In a separate phase III
study of patients (N = 71) with CD25? stage
IB–III CTCL with C4 previous treatments (stage
IVA allowed if they had C1 previous therapies
fail), [68, 69] 53/71 of patients (75%) had
significant pruritus at baseline, of whom 36
(68%) had a clinically significant improvement
(decrease of C20 mm) [68]. All 17 responders
and 13/23 patients (57%) with SD with
clinically significant pruritus at baseline
showed significant improvement [68]. The
median decrease in pruritus was 22 mm in
responders (n = 21; 50% decrease from median
at baseline; P\0.05) and 20 mm in
nonresponders (n = 45; 6% decrease from
median at baseline) [69].
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Vorinostat
Pan-HDAC inhibitor [54] vorinostat (oral) is
approved for patients with CTCL with
progressive, persistent, or recurrent disease on
or following two systemic therapies [70]. In the
initial phase II study in patients (N = 33) with
stage IA–IVB CTCL refractory or intolerant to
conventional therapy, 31 patients had a
baseline pruritus score [median of 8 (range
0–10)] and 14 patients (45%) experienced
pruritus relief, 3 of whom had complete
resolution of pruritus [71]. Among patients
with baseline pruritus scores of 3–6 and 7–10,
33% and 59% experienced relief, respectively,
typically within 4 weeks of study start. The
overall mean reduction in pruritus score was 3,
and patients with SS who did not achieve
objective responses were able to achieve
pruritus relief. In a phase IIb study in patients
(N = 74) with stage CIB CTCL and C2 prior
systemic therapies (1 of which must be
bexarotene unless not tolerated), 21/65
patients (32%) with a baseline pruritus score
C3 experienced pruritus relief [72]. Of 30
patients with a baseline score 7–10, 13 (43%)
experienced pruritus relief, including 5/16
patients with SS; 30% achieved a score\3 at 2
or more consecutive visits. Of 21 patients with
an objective response, 10 (47%) experienced
pruritus relief; 13/51 nonresponders (26%)
experienced pruritus relief [72]. For patients
with stage CIIB disease, median time to and
duration of pruritus relief was 16 days and
3.7 months, respectively. In a phase I study of
vorinostat in combination with bexarotene in
patients (N = 23) with stage CIB CTCL
refractory to C1 prior systemic therapy (not
including bexarotene), 7/23 patients (30%)
experienced pruritus relief, including
nonresponders [73].
Additional Agents
Anti-CD52 monoclonal antibody alemtuzumab
(IV) is an agent included in recommendations
for the treatment of stage C3 MF/SS with disease
progressive or refractory to multiple prior
therapies [45]. In a phase II study in patients
(N = 22) with CD52? stage II–IV MF/SS
previously treated with B5 systemic treatments
(and not responding adequately to PUVA,
radiotherapy, chemotherapy, or interferon
alpha), median VAS was 80 mm at baseline
and 20 mm at treatment end in 17 evaluable
patients [74]. Median VAS was 80 mm for
objective responders (n = 11) and 60 mm for
nonresponders (n = 6) at baseline and 10 and
50 mm, respectively, at treatment end. Three of
six nonresponders had best VAS score
reductions of C10 mm [74]. In a phase II study
of patients (N = 8) with stage IIB-IV relapsed/
refractory CTCL, four patients (50%) reported
significant improvement in pruritus [75].
Extracorporeal photopheresis is a
recommended treatment for MF/SS,
particularly for patients with blood
involvement [45]. In a retrospective single
center study of patients (N = 55) with stage
III–IVB SS, 37/44 (84%) responders had [50%
improvement in pruritus [76]. Low-dose
methotrexate is also included in NCCN
recommendations, and has a history of being
used to treat patients with CTCL [45, 77]. The
impact of methotrexate on CTCL-related
pruritus has not been well documented, but
anecdotal information suggests the potential for
pruritus reduction [6]. Case study data of
patients treated with interferon-a also report a
decrease in pruritus [78].
The remaining agents discussed are
investigational and are not currently approved
or recommended by the NCCN. In a phase II
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study of the anti-CD4 monoclonal antibody
zanolimumab (IV) in patients (N = 47) with
refractory stage IB–IVB MF/SS, 11/13 responding
patients (85%) and 13/25 nonresponders (52%)
reported improvement in pruritus severity [79].
In a phase II study of the pan-HDAC inhibitor
[54] belinostat (IV) in patients (N = 29) with
relapsed/refractory stage IB–IVB CTCL who
received C1 prior systemic therapy, [80] 7/15
patients with baseline pruritus C3 had pruritus
relief, including 3/6 with severe pruritus at
baseline [80]. In a phase II study of the
pan-HDAC inhibitor [54] panobinostat (oral)
in patients (N = 139) with stage IB-IVA MF or SS
who have C2 prior systemic therapies fail, 24/97
patients (25%) with baseline pruritus greater
than the standard deviation of the total group
experienced pruritus relief [81].
SUMMARY
AND RECOMMENDATIONS
Of all the anti-CTCL agents surveyed, HDAC
inhibitors, romidepsin and vorinostat, have the
most detailed published data on reduction of
pruritus [22, 56, 71, 72]. Romidepsin and
vorinostat studies used similar standards for
pruritus assessment and analysed similar
categories. Trials for romidepsin/vorinostat
utilized a 100-mm/10-point patient-assessed
VAS and defined significant pruritus reduction
as C30 mm/3 points; only the romidepsin study
required this for C2 consecutive cycles. The
definition of complete resolution was more
stringent in the study with romidepsin,
requiring VAS = 0 for C8 vs C4 consecutive
weeks [56, 71]. Subanalyses of the romidepsin
study also showed that patients experienced
pruritus reduction irrespective of disease
compartment involvement, and in
difficult-to-treat populations including patients
with cutaneous tumours, folliculotropic MF,
and those with prior chemotherapies [58–60].
Importantly, vorinostat trials allowed the use of
concomitant anti-pruritic medications, which
could impact results, whereas the romidepsin
trial did not [56, 71, 72]. Although reported
rates of significant pruritus reduction were
similar for the two agents, this confounding
factor must be considered. The durability of
significant pruritus reduction was longer with
romidepsin, even without concomitant
anti-pruritic medications. Romidepsin has also
been shown to produce durable clinical
responses in patients with CTCL (median
duration of response [DOR] 14–15 months)
compared with vorinostat (median DOR
4–5? mo) [56, 71, 72, 82].
New-generation HDAC inhibitor belinostat
also used similar measures for pruritus
assessments as romidepsin and vorinostat,[80]
likely intentionally aligned due to precedent
and for ease of comparison. Studies of
single-agent bexarotene and DD also report
detailed pruritus data; however, variations in
assessments make comparisons with other
agents difficult. Bexarotene studies used a 0–8
scale of B5 index lesions and did not define
significant pruritus reduction [62, 63]. However,
more recent combination studies did use a
100-mm VAS [64, 65]. DD studies used a
100-mm VAS [67–69]; however, when
specified, the definition of significant
reduction was less rigorous, at C20 mm [68].
Both bexarotene and DD studies allowed
concomitant anti-pruritic medications
[62, 63, 67–69].
While a review of literature demonstrates
that pruritus reduction is recognized as an
important aspect of treating CTCL, some
studies of anti-lymphoma agents published in
recent years include only a minimal analysis of
pruritus [79–81]. None of the studies surveyed
used pruritus as the primary endpoint, and
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existing pruritus data are difficult to compare
across studies because the methods for assessing
pruritus and reporting pruritus reduction are
not standardized, although more recent studies
more uniformly use a 100-mm/10-point VAS
[64, 73, 80, 83]. Broad suggestions for
assessment of pruritus have been published as
part of a consensus statement on clinical
endpoints and response criteria in CTCL
(Table 2), but they lack definitive thresholds
for clinical relevance [84].
Detailed recommendations regarding
treatment selection based on pruritus
reduction are difficult to make due to the
nonstandardized ways in which pruritus data
are gathered and presented across clinical trials
of different agents. However, particularly for the
approved agents, clinicians may consider
initiating systemic treatment in patients with
earlier stage disease who are struggling with
pruritus. The impact of romidepsin on pruritus
is well characterized, particularly because
concomitant anti-pruritic treatments were not
allowed during the studies, and romidepsin
produces durable responses to treatment as
well as durable pruritus reductions [22, 56].
Oral administration of vorinostat and
bexarotene may be beneficial, particularly for
early-stage patients who are not prepared for IV
treatment. However, it is unclear whether the
reported pruritus reductions are a result of the
drug or concomitant anti-pruritic medications
[62, 63, 71, 72]. This review provides a summary
of what is currently known regarding the
anti-pruritic properties of agents for the
treatment of CTCL—both those approved and
those in clinical development. While
comparisons are difficult to make, it is clear
that anti-lymphoma agents can reduce pruritus
in patients with CTCL.
Table 2 ISCL, USCLC and Cutaneous Lymphoma Task Force of
the European Organisation for Research and Treatment of Cancer
(EORTC) Consensus Recommendations for Pruritus Assessments in
cutaneous T-cell lymphomas Clinical Studies [84]
Method for quantiﬁcation Severity of pruritus should be quantiﬁed using a VAS (number on scale not deﬁned)
Deﬁnition of signiﬁcant pruritus at
baseline
Not deﬁned, though recommendations assert the need to deﬁne
Deﬁnition of clinically signiﬁcant
change or threshold
Not deﬁned, though recommendations assert the need to deﬁne
Comedications Factors that could independently affect pruritus should be eliminated
Any concomitant anti-pruritic agents should be at a stable dose or discontinued
when making comparative pruritus measurements
No claim of absence or resolution of pruritus should be made with concomitant use
of anti-pruritic treatments
Appropriate terminology General terms that imply complete resolution (e.g., ‘‘relief’’) should be avoided when
referring to reduction or change in VAS
Relationship to disease response Changes in pruritus should be correlated to disease response to put results in
perspective
EORTC European Organisation for Research and Treatment of Cancer, ISCL International Society for Cutaneous
Lymphoma, USCLC United States Cutaneous Lymphoma Consortium, VAS visual analog scale
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